Clinical Trial Results:
A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia
Summary
|
|
EudraCT number |
2013-000522-58 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Sep 2021
|
First version publication date |
10 Sep 2021
|
Other versions |
|
Summary report(s) |
NPM001_final report-Abschlussbericht_20160729 NPM001_Report Synopsis of Study_20201207 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.